D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma

British Journal of Haematology

Volumn 161, Issue 6, 2013, Pages 802-810

  Gerrie, Alina S ^a   Mikhael, Joseph R ^b   Cheng, Lu ^c   Jiang, Haiyan ^c   Kukreti, Vishal ^c   Panzarella, Tony ^c   Reece, Donna ^c   Stewart, Keith A ^b   Trieu, Young ^c   Trudel, Suzanne ^c   Chen, Christine I ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MAYO CLINIC   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

DPACE; Multiple myeloma; Refractory; Thalidomide; Therapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; THALIDOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOMATOUS MENINGITIS; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE OVERLOAD; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY FAILURE; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SENSORY NEUROPATHY; SUPRAVENTRICULAR TACHYCARDIA; TERTIARY HEALTH CARE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; SALVAGE THERAPY; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84878521447     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12325     Document Type: Article

References (20)

1. Allison, P.D. (2010) Survival Analysis Using SAS: Practical Guide, 2nd edn. SAS Publishing, Cary, NC.
2. Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. & Crowley, J. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 1021-1030.
3. Barlogie, B., Anaissie, E., van Rhee, F., Haessler, J., Hollmig, K., Pineda-Roman, M., Cottler-Fox, M., Mohiuddin, A., Alsayed, Y., Tricot, G., Bolejack, V., Zangari, M., Epstein, J., Petty, N., Steward, D., Jenkins, B., Gurley, J., Sullivan, E., Crowley, J. & Shaughnessy, Jr, J.D. (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology, 138, 176-185.
4. Crowley, J. & Hu, M. (1977) Covariance analysis of heart transplant survival data. Journal of the American Statistical Association, 27, 27-36.
5. Dadacaridou, M., Papanicolaou, X., Maltesas, D., Megalakaki, C., Patos, P., Panteli, K., Repousis, P. & Mitsouli-Mentzikof, C. (2007) Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. Journal of BUON, 12, 41-44.
6. Dimopoulos, M., Lacy, M.Q., Moreau, P., Weisel, K.C., Song, K.W., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., Yu, X., Sternas, L., Jacques, C.J., Zaki, M. & J.F ., S.M. (2012) Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: a phase 3, multicenter, randomized, open-lable study. Blood (ASH Annual Meeting Abstracts), 120, LBA-6.
7. Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J.S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., Dimopoulos, M., Comenzo, R., Einsele, H., Barlogie, B., Anderson, K., Gertz, M., Harousseau, J.L., Attal, M., Tosi, P., Sonneveld, P., Boccadoro, M., Morgan, G., Richardson, P., Sezer, O., Mateos, M.V., Cavo, M., Joshua, D., Turesson, I., Chen, W., Shimizu, K., Powles, R., Rajkumar, S.V. & Durie, B.G. (2009) International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia, 23, 215-224.
8. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P. & Morgan, G. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 2220.
9. Fisher, L.D. & Lin, D.Y. (1999) Time-dependent covariates in the Cox proportional-hazards regression model. Annual Review of Public Health, 20, 145-157.
10. Harousseau, J.L., Attal, M., Avet-Loiseau, H., Marit, G., Caillot, D., Mohty, M., Lenain, P., Hulin, C., Facon, T., Casassus, P., Michallet, M., Maisonneuve, H., Benboubker, L., Maloisel, F., Petillon, M.O., Webb, I., Mathiot, C. & Moreau, P. (2010) Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. Journal of Clinical Oncology, 28, 4621-4629.
11. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
12. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. & Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516-2520.
13. Lee, C.K., Barlogie, B., Munshi, N., Zangari, M., Fassas, A., Jacobson, J., van Rhee, F., Cottler-Fox, M., Muwalla, F. & Tricot, G. (2003) DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. Journal of Clinical Oncology, 21, 2732-2739.
14. Pineda-Roman, M., Zangari, M., Haessler, J., Anaissie, E., Tricot, G., van Rhee, F., Crowley, J., Shaughnessy, Jr, J.D. & Barlogie, B. (2008) Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. British Journal of Haematology, 140, 625-634.
15. Rajkumar, S.V. (2012) Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? American Society of Hematology Education Program, 2012, 354-361.
16. Rajkumar, S.V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J.B. & Blade, J. (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology, 26, 2171-2177.
17. Rajkumar, S.V., Jacobus, S., Callander, N.S., Fonseca, R., Vesole, D.H., Williams, M.E., Abonour, R., Siegel, D.S., Katz, M. & Greipp, P.R. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol, 11, 29-37.
18. Siegel, D.S., Martin, T., Wang, M., Vij, R., Jakubowiak, A.J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N., Alsina, M., Chanan-Khan, A., Buadi, F., Reu, F.J., Somlo, G., Zonder, J., Song, K., Stewart, A.K., Stadtmauer, E., Kunkel, L., Wear, S., Wong, A.F., Orlowski, R.Z. & Jagannath, S. (2012) A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood, 120, 2817-2825.
19. Srikanth, M., Davies, F.E., Wu, P., Jenner, M.W., Ethell, M.E., Potter, M.N., Shaw, B.E., Saso, R.M., Dines, S. & Morgan, G.J. (2008) Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE. European Journal of Haematology, 81, 432-436.
20. Zangari, M., van Rhee, F., Anaissie, E., Pineda-Roman, M., Haessler, J., Crowley, J. & Barlogie, B. (2008) Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. British Journal of Haematology, 141, 433-444.